McClellan on PAT
This article was originally published in The Tan Sheet
Executive Summary
FDA will publish draft guidance on process analytical technology in September, Commissioner Mark McClellan, MD/PhD, tells Product Quality Research Institute workshop participants on Aug. 5. "I hope you will all have a chance in September...to read our new guidance document that we will be releasing on the use of process analytical technology in making possible innovations in drug manufacturing and quality assurance," he says. The draft guidance is expected to draw from the agency's existing guidance on 21 CFR Part 11 electronic record/electronic signatures (1"The Tan Sheet" Oct. 28, 2002, p. 12)...
You may also be interested in...
PAT Guidance Will Draw From Existing Electronic Records Guidances
FDA plans to draw from existing guidances to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.